Giri S N, Hyde D M, Hollinger M A
Department of Veterinary Pharmacology and Toxicology, University of California, Davis 95616.
Thorax. 1993 Oct;48(10):959-66. doi: 10.1136/thx.48.10.959.
Increased production of transforming growth factor beta (TGF-beta) seems to have an important role in the pathophysiology of bleomycin induced lung fibrosis. This is attributed to the ability of TGF-beta to stimulate infiltration of inflammatory cells and promote synthesis of connective tissue, leading to collagen deposition.
The study was designed to evaluate the antifibrotic potential of TGF-beta antibody in mice treated with bleomycin, which is a model of lung fibrosis. Under methoxyflurane anaesthesia, each mouse received intratracheally either 50 microliters sterile isotonic saline or 0.125 units bleomycin in 50 microliters. Within five minutes after the instillation, mice received into the tail vein 100 microliters non-immune rabbit IgG, TGF-beta 2 antibody, or a combination of TGF-beta 2 and TGF-beta 1 antibodies at various dose regimens. Mice were killed 14 days after the instillation and their lungs processed for morphological and biochemical studies.
Administration of 250 micrograms of TGF-beta 2 antibody after instillation of bleomycin followed by 100 micrograms on day 5 and 100 micrograms on day 9 significantly reduced the bleomycin induced increases in the accumulation of lung collagen from 445.8 (42.3) micrograms/lung to 336.7 (56.6) micrograms/lung at 14 days. Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days.
These results suggest that TGF-beta has an important role in the aetiology of bleomycin induced lung fibrosis; the neutralisation of TGF-beta by systemic treatment with its antibodies offers a new mode of pharmacological intervention which may be useful in treating lung fibrosis.
转化生长因子β(TGF-β)产量增加似乎在博来霉素诱导的肺纤维化病理生理学中起重要作用。这归因于TGF-β刺激炎性细胞浸润和促进结缔组织合成的能力,从而导致胶原蛋白沉积。
本研究旨在评估TGF-β抗体对博来霉素处理的小鼠(肺纤维化模型)的抗纤维化潜力。在甲氧氟烷麻醉下,每只小鼠经气管内给予50微升无菌等渗盐水或50微升含0.125单位博来霉素的溶液。滴注后5分钟内,小鼠经尾静脉接受100微升非免疫兔IgG、TGF-β2抗体或不同剂量方案的TGF-β2和TGF-β1抗体组合。滴注后14天处死小鼠,取其肺组织进行形态学和生化研究。
博来霉素滴注后给予250微克TGF-β2抗体,第5天给予100微克,第9天给予100微克,显著降低了博来霉素诱导的肺胶原蛋白积累,14天时从445.8(42.3)微克/肺降至336.7(56.6)微克/肺。同样,博来霉素滴注后联合给予250微克TGF-β2抗体和250微克TGF-β1抗体,第5天各给予100微克,也显著降低了博来霉素诱导的14天时肺胶原蛋白积累增加和髓过氧化物酶活性。
这些结果表明TGF-β在博来霉素诱导的肺纤维化病因中起重要作用;用其抗体进行全身治疗中和TGF-β提供了一种新的药理干预模式,可能对治疗肺纤维化有用。